Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced a strategic initiative to explore ibogaine-based therapeutics for traumatic brain injury (TBI) and related neuropsychiatric conditions. The company has filed a provisional U.S. patent application covering compositions and methods using ibogaine and related compounds to treat TBI, post-traumatic stress disorder (PTSD) and associated disorders.
This move marks a significant expansion of Silo Pharma's pipeline into the underserved area of TBI, a condition that affects millions worldwide and currently lacks effective pharmacological treatments. By leveraging ibogaine, a naturally occurring psychoactive substance known for its potential in addiction treatment, the company aims to address the complex pathophysiology of TBI, which often leads to chronic neuropsychiatric sequelae.
The initiative underscores Silo Pharma's commitment to developing therapeutics for underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company's portfolio already includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories.
The filing of the provisional patent application is a crucial step in protecting the intellectual property surrounding the use of ibogaine for TBI and related conditions. If successful, this could open new avenues for treatment options for patients suffering from TBI, a condition for which current standard of care is largely supportive and symptomatic.
For more details on the press release, visit https://ibn.fm/HdWHG. To stay updated on Silo Pharma news, visit their newsroom at https://ibn.fm/SILO.
